ClinicalTrials.gg
TerminatedNCT00931606Updated Sep 13, 2023Results posted

Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)

A Phase 2 interventional study of Sotatercept and Placebo in Chemotherapy Induced Anemia, sponsored by Merck Sharp & Dohme LLC. Terminated at 39 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Why this study was terminated
administrative reasons (slow patient enrollment)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.

Enrollment
267th of 395
30 · median 72
Started
2009
with 12 others
Phase 2
109 of 464
9 open now
Registered
155th of 464
by date

Among the 464 studies in Anemia with a site in United States, this one is the 267th largest by enrollment of the 395 interventional ones that give a count, is one of 13 that started in 2009, is one of 109 in phase 2, and was the 155th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 464 studies in Anemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the percentage of participants in each sotatercept dose regimen who achieve a hematopoietic response during the treatment period including up to 2 months after the last dose of sotatercept treatment of chemotherapy-induced anemia (CIA) in participants with metastatic breast cancer. Hematopoietic response was defined as an increase in hemoglobin concentration of ≥ 1 g/dL relative to baseline for 28 consecutive days during the treatment period including up to 2 months after the last dose of sotatercept in the absence of red blood cell (RBC) transfusion or treatment with an erythropoiesis-stimulating agent (ESA).

03

Conditions studied

  • Chemotherapy Induced Anemia

Keywords

  • anemia
  • metastatic
  • breast
  • cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a confirmed diagnosis of breast cancer documented by cytology or .
  • Has evidence of breast cancer with a minimum of one lesion per v 1.1 (RECIST v 1.1) criteria.
  • Is receiving a chemotherapy regimen including one of the following: anthracycline, taxane, gemcitabine, vinorelbine or capecitabine.
  • Has planned treatment with the same chemotherapy regimen for a minimum of 9 weeks after Day 1 of study intervention administration.
  • ≥ 30 days elapsed (from Day 1) since previous treatment with an erythropoiesis stimulating agent (ESA) (including treatment with intravenous (IV) iron) for chemotherapy induced anemia.
  • ≥ 7 days elapsed (from Day 1) since the last red blood cell (RBC) transfusion and receipt of ≤ 2 units of blood in the past 30 days.
  • of ≥ 6 months.

Exclusion criteria

Exclusion Criteria:

  • Has had prior radiation therapy to > 20% of the whole skeleton.
  • Has had > 5 prior chemotherapy treatment regimens for breast cancer.
  • Has a history of or hereditary hemolysis or gastrointestinal bleeding.
  • Has pulmonary, endocrine, neurologic, gastrointestinal, hepatic or genitourinary disease unrelated to underlying hematologic disorder.
  • Has heart failure as classified by the (NYHA) classification of 3 or higher.
  • Has a recent history of thrombosis, deep vein thrombosis (DVT), pulmonary emboli, or embolic stroke, occurring within the last 6 months.
  • Has untreated central nervous system (CNS) metastases or treated with whole brain radiotherapy \< 6 months prior to Day 1.
  • Has a diagnosis of a myeloid or known history of myelodysplasia.
  • Has a history of second malignancy within 5 years (except excised and cured basal cell carcinoma, squamous cell carcinoma of the skin or cervical carcinoma in situ).
  • Has had administration of IV antibiotics or febrile (temperature elevation > 38 ° C) within 14 days of Day 1.
  • Has uncontrolled hypertension.
  • Has known history of surface antigen (HBsAg and HB core antibody (Ab)), (HIV) antibody or active .
  • Has clinically significant iron (transferrin saturation \< 20%), vitamin B12, or folate deficiency.
  • Has a history of anemia as a result of inherited hemoglobinopathy such as sickle cell anemia or thalassemia.
  • Has a history of autoimmune or hereditary hemolysis; active gastrointestinal bleeding (within the last 6 months as compared to Day 1).
  • Has received treatment with another drug or device within 1 month prior to Day 1.
  • Is pregnant or lactating.
  • Has a history of severe allergic or anaphylactic reactions or to recombinant proteins or in the investigational product.
  • Has had major surgery within 30 days prior to Day 1 (patients must have completely recovered from any previous surgery prior to Day 1).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Sotatercept 0.1 mg/kg

    Participants will receive sotatercept 0.1 mg/kg subcutaneously every 28 days up to 4 doses.

    Biological: Sotatercept

  • Experimental
    Sotatercept 0.3 mg/kg

    Participants will receive sotatercept 0.3 mg/kg subcutaneously every 28 days up to 4 doses.

    Biological: Sotatercept

  • Experimental
    Sotatercept 0.5 mg/kg

    Participants will receive sotatercept 0.5 mg/kg subcutaneously every 28 days up to 4 doses.

    Biological: Sotatercept

  • Placebo comparator
    Placebo

    Participants will receive placebo subcutaneously every 28 days up to 4 doses.

    Drug: Placebo

Interventions

  • BiologicalSotatercept

    up to 4 subcutaneous doses of sotatercept given once every 28 days

    Also known as: ACE-011

  • DrugPlacebo

    up to 4 subcutaneous doses of placebo given once every 28 days

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a Hematopoietic Response

    Hematopoietic response rate is defined as the percentage of participants who had increase in hemoglobin concentration of ≥ 1 g/dL relative to baseline for 28 consecutive days during the treatment period including up to 2 months after the last dose of study treatment in the absence of red blood cell (RBC) transfusion or treatment with an erythropoiesis-stimulating agent (ESA). The percentage of participants who achieved hematopoietic response is presented.

    Time frame: Baseline and Up to ~145 Days

Secondary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced AEs is reported.

    Time frame: Up to ~175 Days

  2. Number of Participants Who Discontinued Study Intervention Due to an Adverse Event

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study intervention due to AEs is reported.

    Time frame: Up to ~85 Days

  3. Percentage of Participants Achieving an Increase From Baseline Hemoglobin of ≥ 2 g/dL

    Percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL for 28 consecutive days during the treatment period and up to 2 months after the last dose of study treatment in the absence of RBC transfusion or treatment with an ESA. The percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL for 28 consecutive days is presented.

    Time frame: Baseline and Up to ~145 Days

  4. Percentage of Participants Achieving an Increase From Baseline Hemoglobin ≥ 11 g/dL

    Percentage of participants achieving hemoglobin ≥ 11 g/dL for 28 consecutive days during the treatment period and up to 2 months after the last dose of study treatment in the absence of RBC transfusion or treatment with an ESA. The percentage of participants achieving an increase from baseline hemoglobin of ≥ 11 g/dL for 28 consecutive days is presented.

    Time frame: Baseline and Up to ~145 Days

  5. Percentage of Participants Achieving an Increase From Baseline Hemoglobin of ≥2 g/dL and/or Hemoglobin ≥ 11 g/dL

    Percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL and/or hemoglobin ≥ 11 g/dL for 28 consecutive days during the treatment period and up to 2 months after the last dose of study treatment in the absence of RBC transfusion or treatment with an ESA. The percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL and/or hemoglobin ≥ 11 g/dL for 28 consecutive days is presented.

    Time frame: Baseline and Up to ~145 Days

  6. Duration of Hematopoietic Response for Hemoglobin ≥ 1 g/dL

    Duration of hematopoietic response is defined as the time period from the first time hemoglobin increases at least ≥ 1 g/dL from baseline to the last time there is hemoglobin ≥ 1 g/dL increase from baseline. Duration of response is only calculated for a responder and will be at least 28 days. The duration of response is only calculated for a patient who meets the primary efficacy endpoint. The data for duration of response for ≥ 1 g/dL from baseline is presented.

    Time frame: Baseline and Up to ~145 Days

  7. Duration of Hematopoietic Response for Hemoglobin ≥ 2 g/dL

    Duration of hematopoietic response is defined as the time period from the first time hemoglobin increases at least ≥ 2 g/dL from baseline to the last time there is hemoglobin ≥ 2 g/dL increase from baseline. Duration of response is only calculated for a responder and will be at least 28 days. The duration of response is only calculated for a patient who meets the primary efficacy endpoint. The data for duration of response for hemoglobin ≥ 2 g/dL from baseline is presented.

    Time frame: Baseline and Up to ~145 Days

  8. Duration of Hematopoietic Response for Hemoglobin ≥ 11 g/dL

    Duration of hematopoietic response is defined as the time period from the first time hemoglobin increases at least ≥ 11 g/dL from baseline to the last time there is hemoglobin ≥ 11 g/dL increase from baseline. Duration of response is only calculated for a responder and will be at least 28 days. The duration of response is only calculated for a patient who meets the primary efficacy endpoint. The data for duration of response for hemoglobin ≥ 11 g/dL from baseline is presented.

    Time frame: Baseline and Up to ~145 Days

  9. Duration of Hematopoietic Response for Hemoglobin Increases ≥ 1 g/dL and/or Hemoglobin Concentration ≥ 11 g/dL

    Duration of hematopoietic response is defined as the time period the first time hemoglobin increases ≥ 1 g/dL and/or hemoglobin concentration is ≥ 11 g/dL from baseline to the last time when the same response is maintained. The data for duration of response for hemoglobin ≥ 1 g/dL and/or hemoglobin concentration ≥ 11 g/dL from baseline is presented.

    Time frame: Baseline and Up to ~145 Days

  10. Duration of Hematopoietic Response for Hemoglobin Increases ≥ 2 g/dL, and/or Hemoglobin Concentration ≥ 11 g/dL

    Duration of hematopoietic response is defined as the time period the first time hemoglobin increases ≥ 2 g/dL, and/or hemoglobin concentration is ≥ 11 g/dL from baseline to the last time when the same response is maintained. The data for duration of response for hemoglobin ≥ 2 g/dL and/or hemoglobin concentration ≥ 11 g/dL from baseline is presented.

    Time frame: Baseline and Up to ~145 Days

  11. Time to Achieve Hematopoietic Response of Hemoglobin ≥ 1 g/dL Increase From Baseline

    Time to achieve hematopoietic response based on ≥ 1 g/dL increase from baseline, is defined as the time from first dose of study treatment to the first hemoglobin increase ≥ 1 g/dL that was maintained for at least 28 consecutive days. The data for time to achieve hematopoietic response for hemoglobin ≥ 1 g/dL from baseline is presented.

    Time frame: Baseline and Up to ~145 Days

  12. Time to Achieve Hematopoietic Response of Hemoglobin ≥ 2 g/dL Increase From Baseline

    Time to achieve hematopoietic response based on ≥ 2 g/dL increase from baseline, is defined as the time from first dose of study treatment to the first hemoglobin increase ≥ 2 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin ≥ 2 g/dL from baseline is presented.

    Time frame: Baseline and Up to ~145 Days

  13. Time to Achieve Hematopoietic Response of Hemoglobin ≥ 11 g/dL From Baseline

    Time to achieve hematopoietic response based on hemoglobin ≥ 11 g/dL, defined as the time from first dose of study treatment to the first hemoglobin ≥ 11 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin ≥ 11 g/dL from baseline is presented.

    Time frame: Baseline and Up to ~145 Days

  14. Time to Achieve Hematopoietic Response of First Hemoglobin Increase ≥ 1 g/dL and/or Hemoglobin ≥ 11 g/dL

    Time to achieve hematopoietic response based on multiple criteria categories, defined as the time from first dose of study treatment to first hemoglobin increase ≥ 1 g/dL and/or hemoglobin ≥ 11 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin increase from baseline ≥ 1 g/dL and/or ≥ 11 g/dL from baseline is presented.

    Time frame: Baseline and Up to ~145 Days

  15. Time to Achieve Hematopoietic Response of First Hemoglobin Increase ≥ 2 g/dL and/or Hemoglobin ≥ 11 g/dL

    Time to achieve hematopoietic response, defined as the time from first dose of study treatment to first hemoglobin increase ≥ 2 g/dL and/or hemoglobin ≥ 11 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin increase from baseline ≥ 2 g/dL and/or ≥ 11 g/dL from baseline is presented.

    Time frame: Baseline and Up to ~145 Days

  16. Percentage of Participants Who Received RBC Transfusion or Treatment With an ESA

    The percentage of participants who received RBC transfusion or treatment with an ESA in each study treatment group as well as within each cycle of each study treatment is presented.

    Time frame: Up to Day 141

  17. Objective Response Rate (ORR) for Target Lesions at Day 64 Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1).

    ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR at Day 64 is presented.

    Time frame: Baseline and Day 64

  18. Objective Tumor Response Rate for Non-target Lesions at Day 64 Using RECIST v 1.1.

    ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR of non-target lesions at Day 64 is presented.

    Time frame: Day 64

  19. Objective Tumor Response Rate for Target Lesions on Day 113 Using RECIST v 1.1.

    ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR at Day 113 is presented.

    Time frame: Day 113

  20. Objective Tumor Response Rate for Non-target Lesions on Day 113 Using RECIST v 1.1.

    ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR of non-target lesions at Day 113 is presented.

    Time frame: Day 113

  21. Progression-free Survival (PFS)

    PFS was defined as the time from start of the chemotherapy regimen (which could have occurred prior to study start and collected as prior anticancer therapy) to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS per RECIST 1.1 is presented.

    Time frame: From start of chemotherapy (which could have occurred prior to study start) up to Study Day 281

07

Results

Posted Sep 13, 2023
Limitations and caveats
This is an acquired study. No restrictions were imposed on time on current chemotherapy prior to study entry, therefore PFS could have gone beyond the study duration. The time from start of current chemotherapy could have occurred prior to study start and collected as prior anticancer therapy, therefore the upper limit of the confidence interval in the "Sotatercept 0.5 mg/kg" arm, "1791.0 days", didn't exceed the timeframe of 281 days after study start.

Participant flow

This study was terminated early after 30 participants were enrolled due to slower than expected rate of enrollment as a result of changes in guidance for the treatment of participants with breast cancer and chemotherapy induced anemia (CIA).

Participant flow — Overall Study
MilestoneSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Started81075
Completed3112
Not completed5963
Withdrew: Death1320
Withdrew: Lost to follow-up0100
Withdrew: Physician decision0030
Withdrew: Sponsor decision1402
Withdrew: Withdrawal by subject3111

Outcome measures

PrimaryPercentage of Participants Who Achieved a Hematopoietic Response

Hematopoietic response rate is defined as the percentage of participants who had increase in hemoglobin concentration of ≥ 1 g/dL relative to baseline for 28 consecutive days during the treatment period including up to 2 months after the last dose of study treatment in the absence of red blood cell (RBC) transfusion or treatment with an erythropoiesis-stimulating agent (ESA). The percentage of participants who achieved hematopoietic response is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved a Hematopoietic Response
Percentage of ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlaceboAll Sotatercept-treated Participants
Overall0 (0 to 52.2)33.3 (7.5 to 70.1)50.0 (6.8 to 93.2)20.0 (0.5 to 71.6)27.8 (9.7 to 53.5)
Received weekly chemotherapy and showed a response0 (0 to 84.2)0 (0 to 84.2)25.0 (2.5 to 100.0)20 (2.5 to 100.0)5.6 (0.5 to 71.6)
Received less frequent chemotherapy and showed a response0 (0 to 70.8)33.3 (9.9 to 81.6)25.0 (0.8 to 90.6)0 (0 to 60.2)22.2 (9.1 to 61.4)
Statistical analysis
  • Sotatercept 0.1 mg/kg vs Placebo · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.3 mg/kg vs Placebo · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.5 mg/kg vs Placebo · Fisher Exact · p = 0.524Clopper and Pearson exact approach
  • Placebo vs All Sotatercept-treated Participants · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.1 mg/kg vs Placebo · Fisher Exact · p = 0.333Clopper and Pearson exact approach
  • Sotatercept 0.3 mg/kg vs Placebo · Fisher Exact · p = 0.333Clopper and Pearson exact approach
  • Placebo vs All Sotatercept-treated Participants · Fisher Exact · p = 0.333Clopper and Pearson exact approach
  • Sotatercept 0.3 mg/kg vs Placebo · Fisher Exact · p = 0.236Clopper and Pearson exact approach
  • Sotatercept 0.5 mg/kg vs Placebo · Fisher Exact · p = 0.429Clopper and Pearson exact approach
  • Placebo vs All Sotatercept-treated Participants · Fisher Exact · p = 0.519Clopper and Pearson exact approach
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experienced AEs is reported.

Time frame:
Up to ~175 Days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Number of Participants Who Experienced an Adverse Event (AE)6775
SecondaryNumber of Participants Who Discontinued Study Intervention Due to an Adverse Event

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study intervention due to AEs is reported.

Time frame:
Up to ~85 Days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Intervention Due to an Adverse Event
ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Number of Participants Who Discontinued Study Intervention Due to an Adverse Event1041
SecondaryPercentage of Participants Achieving an Increase From Baseline Hemoglobin of ≥ 2 g/dL

Percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL for 28 consecutive days during the treatment period and up to 2 months after the last dose of study treatment in the absence of RBC transfusion or treatment with an ESA. The percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL for 28 consecutive days is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an Increase From Baseline Hemoglobin of ≥ 2 g/dL
Percentage of ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlaceboAll Sotatercept-treated Participants
Overall0 (0 to 52.2)11.1 (0.3 to 48.2)0 (0 to 60.2)0 (0 to 52.2)5.6 (0.1 to 27.3)
Received weekly chemotherapy and showed a response0 (0 to 84.2)0 (0 to 84.2)0 (0 to 97.5)0 (0 to 97.5)0 (0 to 52.2)
Received less frequent chemotherapy and showed a response0 (0 to 70.8)11.1 (0.4 to 57.9)0 (0 to 70.8)0 (0 to 60.2)5.6 (0.2 to 36.0)
Statistical analysis
  • Sotatercept 0.3 mg/kg vs Placebo · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Placebo vs All Sotatercept-treated Participants · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.3 mg/kg vs Placebo · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Placebo vs All Sotatercept-treated Participants · Fisher Exact · p = >0.999Clopper and Pearson exact approach
SecondaryPercentage of Participants Achieving an Increase From Baseline Hemoglobin ≥ 11 g/dL

Percentage of participants achieving hemoglobin ≥ 11 g/dL for 28 consecutive days during the treatment period and up to 2 months after the last dose of study treatment in the absence of RBC transfusion or treatment with an ESA. The percentage of participants achieving an increase from baseline hemoglobin of ≥ 11 g/dL for 28 consecutive days is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an Increase From Baseline Hemoglobin ≥ 11 g/dL
Percentage of ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlaceboAll Sotatercept-treated Participants
Overall20.0 (0.5 to 71.6)22.2 (2.8 to 60.0)75.0 (19.4 to 99.4)20.0 (0.5 to 71.6)33.3 (13.3 to 59.0)
Received weekly chemotherapy and showed a response0 (0 to 84.2)11.1 (1.3 to 98.7)25.0 (2.5 to 100.0)20.0 (2.5 to 100.0)11.1 (5.3 to 85.3)
Received less frequent chemotherapy and showed a response20.0 (0.8 to 90.6)11.1 (0.4 to 57.9)50.0 (9.4 to 99.2)0 (0 to 60.2)22.2 (9.1 to 61.4)
Statistical analysis
  • Sotatercept 0.1 mg/kg vs Placebo · Fisher Exact · p = >0.999 (P-values greater than 0.999, are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.3 mg/kg vs Placebo · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.5 mg/kg vs Placebo · Fisher Exact · p = 0.206Clopper and Pearson exact approach
  • Placebo vs All Sotatercept-treated Participants · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.1 mg/kg vs Placebo · Fisher Exact · p = 0.333Clopper and Pearson exact approach
  • Sotatercept 0.3 mg/kg vs Placebo · Fisher Exact · p = >0.999 (P-values greater than 0.999, are reported as "\>0.999".)Clopper and Pearson exact approach
  • Placebo vs All Sotatercept-treated Participants · Fisher Exact · p = >0.999 (P-values greater than 0.999, are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.1 mg/kg vs Placebo · Fisher Exact · p = 0.429Clopper and Pearson exact approach
  • Sotatercept 0.3 mg/kg vs Placebo · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.5 mg/kg vs Placebo · Fisher Exact · p = 0.143Clopper and Pearson exact approach
  • Placebo vs All Sotatercept-treated Participants · Fisher Exact · p = 0.519Clopper and Pearson exact approach
SecondaryPercentage of Participants Achieving an Increase From Baseline Hemoglobin of ≥2 g/dL and/or Hemoglobin ≥ 11 g/dL

Percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL and/or hemoglobin ≥ 11 g/dL for 28 consecutive days during the treatment period and up to 2 months after the last dose of study treatment in the absence of RBC transfusion or treatment with an ESA. The percentage of participants achieving an increase from baseline hemoglobin of ≥ 2 g/dL and/or hemoglobin ≥ 11 g/dL for 28 consecutive days is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an Increase From Baseline Hemoglobin of ≥2 g/dL and/or Hemoglobin ≥ 11 g/dL
Percentage of ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlaceboAll Sotatercept-treated Participants
Overall20.0 (0.5 to 71.6)22.2 (2.8 to 60.0)75.0 (19.4 to 99.4)20.0 (0.5 to 71.6)33.3 (13.3 to 59.0)
Received weekly chemotherapy and showed a response0 (0 to 84.2)11.1 (1.3 to 98.7)25.0 (2.5 to 100.0)20.0 (2.5 to 100.0)11.1 (5.3 to 85.3)
Received less frequent chemotherapy and showed a response20.0 (0.8 to 90.6)11.1 (0.4 to 57.9)50.0 (9.4 to 99.2)0 (0 to 60.2)22.2 (9.1 to 61.4)
Statistical analysis
  • Sotatercept 0.1 mg/kg vs Placebo · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.3 mg/kg vs Placebo · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.5 mg/kg vs Placebo · Fisher Exact · p = 0.206Clopper and Pearson exact approach
  • Placebo vs All Sotatercept-treated Participants · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.1 mg/kg vs Placebo · Fisher Exact · p = 0.333Clopper and Pearson exact approach
  • Sotatercept 0.3 mg/kg vs Placebo · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Placebo vs All Sotatercept-treated Participants · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.1 mg/kg vs Placebo · Fisher Exact · p = 0.429Clopper and Pearson exact approach
  • Sotatercept 0.3 mg/kg vs Placebo · Fisher Exact · p = >0.999 (P-values greater than 0.999 are reported as "\>0.999".)Clopper and Pearson exact approach
  • Sotatercept 0.5 mg/kg vs Placebo · Fisher Exact · p = 0.143Clopper and Pearson exact approach
  • Placebo vs All Sotatercept-treated Participants · Fisher Exact · p = 0.519Clopper and Pearson exact approach
SecondaryDuration of Hematopoietic Response for Hemoglobin ≥ 1 g/dL

Duration of hematopoietic response is defined as the time period from the first time hemoglobin increases at least ≥ 1 g/dL from baseline to the last time there is hemoglobin ≥ 1 g/dL increase from baseline. Duration of response is only calculated for a responder and will be at least 28 days. The duration of response is only calculated for a patient who meets the primary efficacy endpoint. The data for duration of response for ≥ 1 g/dL from baseline is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Mean · Days
Duration of Hematopoietic Response for Hemoglobin ≥ 1 g/dL
DaysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Duration of Hematopoietic Response for Hemoglobin ≥ 1 g/dL—47.0 ± 20.3046.5 ± 14.8529.0 ± NA
SecondaryDuration of Hematopoietic Response for Hemoglobin ≥ 2 g/dL

Duration of hematopoietic response is defined as the time period from the first time hemoglobin increases at least ≥ 2 g/dL from baseline to the last time there is hemoglobin ≥ 2 g/dL increase from baseline. Duration of response is only calculated for a responder and will be at least 28 days. The duration of response is only calculated for a patient who meets the primary efficacy endpoint. The data for duration of response for hemoglobin ≥ 2 g/dL from baseline is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Mean · Days
Duration of Hematopoietic Response for Hemoglobin ≥ 2 g/dL
DaysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Duration of Hematopoietic Response for Hemoglobin ≥ 2 g/dL—69.0 ± NA——
SecondaryDuration of Hematopoietic Response for Hemoglobin ≥ 11 g/dL

Duration of hematopoietic response is defined as the time period from the first time hemoglobin increases at least ≥ 11 g/dL from baseline to the last time there is hemoglobin ≥ 11 g/dL increase from baseline. Duration of response is only calculated for a responder and will be at least 28 days. The duration of response is only calculated for a patient who meets the primary efficacy endpoint. The data for duration of response for hemoglobin ≥ 11 g/dL from baseline is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Mean · Days
Duration of Hematopoietic Response for Hemoglobin ≥ 11 g/dL
DaysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Duration of Hematopoietic Response for Hemoglobin ≥ 11 g/dL—41.0 ± NA50.0 ± 9.9029.0 ± NA
SecondaryDuration of Hematopoietic Response for Hemoglobin Increases ≥ 1 g/dL and/or Hemoglobin Concentration ≥ 11 g/dL

Duration of hematopoietic response is defined as the time period the first time hemoglobin increases ≥ 1 g/dL and/or hemoglobin concentration is ≥ 11 g/dL from baseline to the last time when the same response is maintained. The data for duration of response for hemoglobin ≥ 1 g/dL and/or hemoglobin concentration ≥ 11 g/dL from baseline is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Mean · Days
Duration of Hematopoietic Response for Hemoglobin Increases ≥ 1 g/dL and/or Hemoglobin Concentration ≥ 11 g/dL
DaysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Duration of Hematopoietic Response for Hemoglobin Increases ≥ 1 g/dL and/or Hemoglobin Concentration ≥ 11 g/dL—47.0 ± 20.3050.0 ± 9.9029.0 ± NA
SecondaryDuration of Hematopoietic Response for Hemoglobin Increases ≥ 2 g/dL, and/or Hemoglobin Concentration ≥ 11 g/dL

Duration of hematopoietic response is defined as the time period the first time hemoglobin increases ≥ 2 g/dL, and/or hemoglobin concentration is ≥ 11 g/dL from baseline to the last time when the same response is maintained. The data for duration of response for hemoglobin ≥ 2 g/dL and/or hemoglobin concentration ≥ 11 g/dL from baseline is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Mean · Days
Duration of Hematopoietic Response for Hemoglobin Increases ≥ 2 g/dL, and/or Hemoglobin Concentration ≥ 11 g/dL
DaysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Duration of Hematopoietic Response for Hemoglobin Increases ≥ 2 g/dL, and/or Hemoglobin Concentration ≥ 11 g/dL—69.0 ± NA50.0 ± 9.9029.0 ± NA
SecondaryTime to Achieve Hematopoietic Response of Hemoglobin ≥ 1 g/dL Increase From Baseline

Time to achieve hematopoietic response based on ≥ 1 g/dL increase from baseline, is defined as the time from first dose of study treatment to the first hemoglobin increase ≥ 1 g/dL that was maintained for at least 28 consecutive days. The data for time to achieve hematopoietic response for hemoglobin ≥ 1 g/dL from baseline is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Median · Days
Time to Achieve Hematopoietic Response of Hemoglobin ≥ 1 g/dL Increase From Baseline
DaysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Time to Achieve Hematopoietic Response of Hemoglobin ≥ 1 g/dL Increase From Baseline—NA (72.0 to NA)NA (6.0 to NA)NA (112 to NA)
SecondaryTime to Achieve Hematopoietic Response of Hemoglobin ≥ 2 g/dL Increase From Baseline

Time to achieve hematopoietic response based on ≥ 2 g/dL increase from baseline, is defined as the time from first dose of study treatment to the first hemoglobin increase ≥ 2 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin ≥ 2 g/dL from baseline is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Median · Days
Time to Achieve Hematopoietic Response of Hemoglobin ≥ 2 g/dL Increase From Baseline
DaysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Time to Achieve Hematopoietic Response of Hemoglobin ≥ 2 g/dL Increase From Baseline—NA (NA to NA)——
SecondaryTime to Achieve Hematopoietic Response of Hemoglobin ≥ 11 g/dL From Baseline

Time to achieve hematopoietic response based on hemoglobin ≥ 11 g/dL, defined as the time from first dose of study treatment to the first hemoglobin ≥ 11 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin ≥ 11 g/dL from baseline is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Median · Days
Time to Achieve Hematopoietic Response of Hemoglobin ≥ 11 g/dL From Baseline
DaysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Time to Achieve Hematopoietic Response of Hemoglobin ≥ 11 g/dL From BaselineNA (28.0 to NA)NA (100.0 to NA)56.0 (6.0 to NA)NA (112.0 to NA)
SecondaryTime to Achieve Hematopoietic Response of First Hemoglobin Increase ≥ 1 g/dL and/or Hemoglobin ≥ 11 g/dL

Time to achieve hematopoietic response based on multiple criteria categories, defined as the time from first dose of study treatment to first hemoglobin increase ≥ 1 g/dL and/or hemoglobin ≥ 11 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin increase from baseline ≥ 1 g/dL and/or ≥ 11 g/dL from baseline is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Median · Days
Time to Achieve Hematopoietic Response of First Hemoglobin Increase ≥ 1 g/dL and/or Hemoglobin ≥ 11 g/dL
DaysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Time to Achieve Hematopoietic Response of First Hemoglobin Increase ≥ 1 g/dL and/or Hemoglobin ≥ 11 g/dLNA (28.0 to NA)NA (21.0 to NA)56.0 (6.0 to NA)NA (112.0 to NA)
SecondaryTime to Achieve Hematopoietic Response of First Hemoglobin Increase ≥ 2 g/dL and/or Hemoglobin ≥ 11 g/dL

Time to achieve hematopoietic response, defined as the time from first dose of study treatment to first hemoglobin increase ≥ 2 g/dL and/or hemoglobin ≥ 11 g/dL that was maintained for at least 28 consecutive days. The data for duration of response for hemoglobin increase from baseline ≥ 2 g/dL and/or ≥ 11 g/dL from baseline is presented.

Time frame:
Baseline and Up to ~145 Days
Reported as:
Median · Days
Time to Achieve Hematopoietic Response of First Hemoglobin Increase ≥ 2 g/dL and/or Hemoglobin ≥ 11 g/dL
DaysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Time to Achieve Hematopoietic Response of First Hemoglobin Increase ≥ 2 g/dL and/or Hemoglobin ≥ 11 g/dLNA (28.0 to NA)NA (NA to NA)56.0 (6.0 to NA)NA (112.0 to NA)
SecondaryPercentage of Participants Who Received RBC Transfusion or Treatment With an ESA

The percentage of participants who received RBC transfusion or treatment with an ESA in each study treatment group as well as within each cycle of each study treatment is presented.

Time frame:
Up to Day 141
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Received RBC Transfusion or Treatment With an ESA
Percentage of ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Overall RBC Transfusions033.325.00
Overall ESAs011.100
Overall Received RBC Transfusions or ESAs044.425.00
Day 1 to Prior to Day 29 RBC Transfusions011.125.00
Day 1 to Prior to Day 29 ESAs0000
Day 1 to Prior to Day 29 Received RBC Transfusions or ESAs011.125.00
Day 29 to Prior to Day 57 RBC Transfusions022.200
Day 29 to Prior to Day 57 ESAs0000
Day 29 to Prior to Day 57 Received RBC Transfusions or ESAs022.200
Day 57 to Prior to Day 85 RBC Transfusions0025.00
Day 57 to Prior to Day 85 ESAs011.100
Day 57 to Prior to Day 85 Received RBC Transfusions or ESAs011.125.00
Day 85 to Prior to Day 141 RBC Transfusions011.125.00
Day 85 to Prior to Day 141 ESAs0000
Day 85 to Prior to Day 141 Received RBC Transfusions or ESAs011.125.00
SecondaryObjective Response Rate (ORR) for Target Lesions at Day 64 Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1).

ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR at Day 64 is presented.

Time frame:
Baseline and Day 64
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) for Target Lesions at Day 64 Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1).
Percentage of ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Complete Response033.300
Partial Response016.700
Stable Disease100.016.7100.050.0
Progressive Disease016.700
Not Evaluable0000
Not Applicable016.7050.0
SecondaryObjective Tumor Response Rate for Non-target Lesions at Day 64 Using RECIST v 1.1.

ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR of non-target lesions at Day 64 is presented.

Time frame:
Day 64
Reported as:
Number · Percentage of Participants
Objective Tumor Response Rate for Non-target Lesions at Day 64 Using RECIST v 1.1.
Percentage of ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Complete Response0000
Progressive Disease50.033.3050.0
Non-complete Response/Non-progressive disease50.050.0100.025.0
Not Evaluable0000
Not Applicable016.7025.0
SecondaryObjective Tumor Response Rate for Target Lesions on Day 113 Using RECIST v 1.1.

ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR at Day 113 is presented.

Time frame:
Day 113
Reported as:
Number · Percentage of Participants
Objective Tumor Response Rate for Target Lesions on Day 113 Using RECIST v 1.1.
Percentage of ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Complete Response0000
Partial Response0000
Stable Disease100.00033.3
Progressive Disease0000
Not Evaluable0000
Not Applicable0100.0100.066.7
SecondaryObjective Tumor Response Rate for Non-target Lesions on Day 113 Using RECIST v 1.1.

ORR is defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR of non-target lesions at Day 113 is presented.

Time frame:
Day 113
Reported as:
Number · Percentage of Participants
Objective Tumor Response Rate for Non-target Lesions on Day 113 Using RECIST v 1.1.
Percentage of ParticipantsSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlacebo
Complete Response0000
Progressive Disease00100.033.3
Non-complete Response/Non-progressive disease100.050.0033.3
Not Evaluable050.000
Not Applicable00033.3
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from start of the chemotherapy regimen (which could have occurred prior to study start and collected as prior anticancer therapy) to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS per RECIST 1.1 is presented.

Time frame:
From start of chemotherapy (which could have occurred prior to study start) up to Study Day 281
Reported as:
Median · Days
Progression-free Survival (PFS)
DaysSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlaceboAll Sotatercept-treated Participants
Progression-free Survival (PFS)188.0 (64.0 to 188.0)196.0 (97.0 to 219.0)187.0 (134.0 to 1791.0)157.0 (84.0 to NA)169.0 (108.0 to 219.0)

Adverse events

Collected over Up to Day 281. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sotatercept 0.1 mg/kg1/8 (12.5%)0/8 (0%)6/8 (75%)
Sotatercept 0.3 mg/kg3/10 (30%)2/10 (20%)7/10 (70%)
Sotatercept 0.5 mg/kg3/7 (42.9%)3/7 (42.9%)7/7 (100%)
Placebo0/5 (0%)1/5 (20%)5/5 (100%)
Total7/30 (23.3%)6/30 (20%)25/30 (83.3%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlaceboTotal
NauseaGastrointestinal disorders0/81/102/70/53/30
VomitingGastrointestinal disorders0/81/102/70/53/30
FatigueGeneral disorders0/80/100/71/51/30
AnaemiaBlood and lymphatic system disorders0/80/101/70/51/30
Gastric ulcer perforationGastrointestinal disorders0/80/101/70/51/30
Peptic ulcerGastrointestinal disorders0/80/101/70/51/30
AstheniaGeneral disorders0/80/101/70/51/30
AnorexiaMetabolism and nutrition disorders0/80/101/70/51/30
DehydrationMetabolism and nutrition disorders0/81/101/70/52/30
Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/81/101/70/52/30
Most frequent other events
Showing 10 of 136
Most frequent other events
EventSotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlaceboTotal
NeutropeniaBlood and lymphatic system disorders4/80/102/73/59/30
NauseaGastrointestinal disorders0/81/102/73/56/30
VomitingGastrointestinal disorders1/80/103/71/55/30
LeukopeniaBlood and lymphatic system disorders3/80/100/72/55/30
DiarrhoeaGastrointestinal disorders0/81/101/72/54/30
AstheniaGeneral disorders3/82/102/72/59/30
FatigueGeneral disorders1/81/102/72/56/30
HeadacheNervous system disorders1/80/102/72/55/30
AnaemiaBlood and lymphatic system disorders1/83/102/71/57/30
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/83/101/70/54/30

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlaceboTotal
Mean51.6 ± 9.3850.8 ± 8.5155.6 ± 12.5349.2 ± 10.6251.9 ± 9.83
Sex: Female, Male
Sex: Female, Male(Participants)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlaceboTotal
Female8107530
Male00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlaceboTotal
American Indian or Alaska Native00011
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White8107429
More than one race00000
Unknown or Not Reported00000
Weight
Weight(Kilograms)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlaceboTotal
Mean67.38 ± 18.33871.80 ± 9.50069.94 ± 9.95379.62 ± 9.92671.49 ± 12.647
Chemotherapy Frequency
Chemotherapy Frequency(Participants)Sotatercept 0.1 mg/kgSotatercept 0.3 mg/kgSotatercept 0.5 mg/kgPlaceboTotal
Weekly22116
Less Frequently686424
08

Study locations

39 sites
  • Investigative Site
    Sedona, Arizona, United States
  • Investigative Site
    Hot Springs, Arkansas, United States
  • Investigative Site
    Beverly Hills, California, United States
  • Investigative Site
    Corona, California, United States
  • Investigative Site
    Fountain Valley, California, United States
  • Investigative Site
    Montebello, California, United States
  • Investigative Site
    Riverside, California, United States
  • Investigative Site
    Denver, Colorado, United States
  • Investigative Site
    Boynton Beach, Florida, United States
  • Investigative Site
    Hinsdale, Illinois, United States
  • Investigative Site
    Evansville, Indiana, United States
  • Investigative Site
    Wichita, Kansas, United States
  • Investigative Site
    Baltimore, Maryland, United States
  • Investigative Site
    Grand Rapids, Michigan, United States
  • Investigative Site
    Tupelo, Mississippi, United States
  • Investigative Site
    Kansas City, Missouri, United States
  • Investigative Site
    Nyack, New York, United States
  • Investigative Site
    Goldsboro, North Carolina, United States
  • Investigative Site
    High Point, North Carolina, United States
  • Investigative Site
    Winston-Salem, North Carolina, United States
  • Investigative Site
    Bismarck, North Dakota, United States
  • Investigative Site
    Middletown, Ohio, United States
  • Investigative Site
    Philadelphia, Pennsylvania, United States
  • Investigative Site
    Charleston, South Carolina, United States
  • Investigative Site
    Austin, Texas, United States
  • Investigative Site
    Dallas, Texas, United States
  • Investigative Site
    Tyler, Texas, United States
  • Investigative Site
    Lacey, Washington, United States
  • Investigative Site
    Krasnodar, Russian Federation
  • Investigative Site
    Moscow (1), Russian Federation
  • Investigative Site
    Moscow (2), Russian Federation
  • Investigative Site
    Nizhny Novgorod, Russian Federation
  • Investigative Site
    Nizhny Novograd (2), Russian Federation
  • Investigative Site
    Pyatigorsk, Russian Federation
  • Investigative Site
    St. Petersburg (1), Russian Federation
  • Investigative Site
    St. Petersburg (2), Russian Federation
  • Investigative Site
    St. Petersburg (3), Russian Federation
  • Investigative Site
    St. Petersburg (4), Russian Federation
  • Investigative Site
    Stavropol, Russian Federation
09

References and documents

Publications

  • Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016 Apr;24(4):1517-25. doi: 10.1007/s00520-015-2929-9. Epub 2015 Sep 14. PubMed 26370220 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2009 to primary completion in Nov 2010, 17 months.

Results were first posted in Sep 2023, 12 years 9 months after primary completion. A results delay was requested in Nov 2017.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2009
First posted
Jul 2, 2009
StartActual
Jun 1, 2009
Primary completionActual
Nov 18, 2010
CompletionActual
Nov 18, 2010
Results delay requested
Nov 14, 2017
Results first posted
Sep 13, 2023
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00931606
Responsible party
Sponsor
First posted
Jul 2, 2009
Start date
Jun 1, 2009
Primary completion
Nov 18, 2010
Completion
Nov 18, 2010
Results posted
Sep 13, 2023
Last update
Sep 13, 2023

Study contacts

Medical Director
study director · Merck Sharp and Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion